|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400093026 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-27 11:29:41 |
|
注册时间: Date of Registration: |
2024-11-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
血细胞多模态AI预警重症儿童生存风险:一项多中心、回顾性临床研究 |
|
Public title: |
Multimodal AI for Predicting Survival Risk in critically ill children: a multicenter, retrospective clinical study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
血细胞多模态AI预警重症儿童生存风险:一项多中心、回顾性临床研究 |
|
Scientific title: |
Multimodal AI for Predicting Survival Risk in critically ill children: a multicenter, retrospective clinical study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
何若雯 |
研究负责人: |
何彦 |
|
Applicant: |
He Ruowen |
Study leader: |
He yan |
|
申请注册联系人电话: Applicant telephone: |
+86 134 3424 0706 |
研究负责人电话: Study leader's telephone: |
+86 138 2442 0986 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1577576652@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
yanhe@i.smu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
南方医科大学珠江医院 |
研究负责人通讯地址: |
南方医科大学珠江医院 |
|
Applicant address: |
Zhujiang Hospital, Southern Medical University |
Study leader's address: |
Zhujiang Hospital, Southern Medical University |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南方医科大学珠江医院检验医学部 |
||
|
Applicant's institution: |
Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University |
||
|
研究负责人所在单位: |
南方医科大学珠江医院检验医学部 |
||
|
Affiliation of the Leader: |
Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-KY-054-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南方医科大学珠江医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Zhujiang Hospital of Southern Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-24 00:00:00 |
||
|
伦理委员会联系人: |
南方医科大学珠江医院医学伦理委员会 |
||
|
Contact Name of the ethic committee: |
Medical Ethics Committee of Zhujiang Hospital of Southern Medical University |
||
|
伦理委员会联系地址: |
广东省广州市海珠区工业大道中253号珠江医院 |
||
|
Contact Address of the ethic committee: |
253 Middle Gongye Avenue, Haizhu District, Guangzhou, Guangdong |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 6278 3254 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
zjyyllxs@126.com |
|
研究实施负责(组长)单位: |
南方医科大学珠江医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhujiang Hospital of Southern Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市海珠区工业大道中253号珠江医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
253 Middle Gongye Avenue, Haizhu District, Guangzhou, Guangdong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国国家优秀青年科学基金项目《肠道菌群标志物研究》 (82022044) |
||||||||||||||||||||||
|
Source(s) of funding: |
The China National Science Fund for Outstanding Young Scholars – The Marker of Human Gut Microbiome (82022044) |
||||||||||||||||||||||
|
Target disease: |
critically ill children |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
通过多中心大规模重症儿童人群队列,探讨基于血细胞多模态数据的AI预测模型能否实现对重症儿童生存风险的早期预警。 |
||||||||||||||||||||||
|
Objectives of Study: |
Exploring the early warning of survival risk in critically ill children through a multi-center large-scale cohort, using an AI prediction model based on multimodal blood cell data. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①于 2018 年 1 月 1 日至 2023 年 3 月 31 日入住 NICU 和 PICU 的患儿; ②年龄<18 周岁,性别不限; ③入院通过迈瑞医疗五分类血液细胞分析仪(包括 BC6000、BC6000PLUS、 BC6800PLUS、BC7500 系列)进行血常规检测,仪器或电脑系统保留相对完整的血细胞多模态数据; ④可获取与本研究相关的相对完整详细的临床病历信息; ⑤反复转入 NICU 或 PICU 者,因每次转入的状况、病因和结局不同,每次均以新病例记入; |
||||||||||||||||||||||
|
Inclusion criteria |
① Infants admitted to NICU and PICU from January 1, 2018, to March 31, 2023; ② Age <18 years, any gender; ③ Patients admitted and underwent routine blood tests using Mindray Medical's five-classification blood cell analyzer (including BC6000, BC6000PLUS, BC6800PLUS, BC7500 series), with the instrument or computer system retaining relatively complete multimodal blood cell data; ④ Accessible and detailed clinical medical records relevant to this study; ⑤ For patients readmitted to NICU or PICU multiple times, each readmission is considered as a new case due to varying conditions, etiology, and outcomes. |
||||||||||||||||||||||
|
排除标准: |
1.入院 24h 内发生心脏骤停或死亡; 2.血液病患儿, 包括缺铁性贫血、 巨幼红细胞性贫血、 遗传性球形红细胞增多症、红细胞葡萄糖-6-磷酸脱氢酶缺乏症、 地中海贫血、 自身免疫性溶血性贫血、 再生障碍性贫血、 免疫性血小板减少症、 急性淋巴细胞白血病、 急性非淋巴细胞白血病、 多发性骨髓瘤、 过敏性紫癜、 骨髓增生异常综合征等; 3.遗传代谢病患儿, 包括半乳糖血症、 黏多糖贮积症、 糖原贮积症、 苯丙酮尿症、白化病、 黑尿症、 次黄嘌呤-鸟嘌呤磷酸核糖转移酶缺陷症、 着色性干皮病、 戈谢病、 Tay-Sachs 病等; 4.染色体疾病患儿, 包括唐氏综合征、 18 三体综合征等; 5.先天性免疫缺陷病患儿; 6.半年内输注血制品的患儿, 包括输注成分血、 人免疫球蛋白等; 7.住院时长<24h 的患儿; 8.因其他病房床位问题而临时过渡在 NICU 或 PICU 的非重症患儿。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Cardiac arrest or death within 24 hours of admission; 2. Children with blood diseases, including iron deficiency anemia, megaloblastic anemia, hereditary spherocytosis, erythrocyte glucose-6-phosphate dehydrogenase deficiency, thalassemia, autoimmune hemolytic anemia, aplastic anemia, immune thrombocytopenia, acute lymphoblastic leukemia, acute non-lymphocytic leukemia, multiple myeloma, Henoch-Schonlein purpura, myelodysplastic syndrome, etc.; 3. Children with hereditary metabolic diseases, including galactosemia, mucopolysaccharidosis, glycogen storage disease, phenylketonuria, albinism, melaturia, hypoxanthine-guanine phosphoribosyltransferase deficiency, xeroderma pigmentosum, Gaucher disease, Tay-Sachs disease, etc.; 4. Children with chromosomal diseases, including Down syndrome, trisomy 18, etc.; 5. Children with congenital immunodeficiency diseases; 6. Children transfused with blood products within half a year, including transfusion of component blood, human immunoglobulin, etc.; 7. Children with a hospital stay of < 24 hours; 8. Non-critically ill children who are temporarily transitioning to the NICU or PICU due to bed problems in other wards. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-03-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-12-01 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
NCBI数据库,预计共享日期:2025年12月31日 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NCBI http://submit.ncbi.nlm.nih.gov/; Expected to be shared on December 31, 2025. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
使用病历记录表、电子采集和管理系统进行数据采集和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use both Case Record Form and Electronic Data Capture for data collection and management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |